Given BAY1082439 treatment can significantly increase the expression of B2M in PTEN-null prostate cancer cells (Fig. 1B and E), this result indicates that BAY-I treatment may induce proliferation and activation of tumor antigen-specific T cells. Here, LINC01194 is linked to prostate carcinoma.